# US 2010/0168199 A1 · Kinase Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168199 A1
- Document ID: US20100168199A1
- Status: Published application
- Kind: A1
- Application number: 12/377,098
- Filed: 2007-08-10
- Published: 2010-07-01
- Earliest claimed: 2006-08-11
- Assignees: Allengan, Inc.
- Inventors: Julie A. Wurster; Richard C. Yee
- Web page: https://patentgrep.com/patent/US20100168199A1

## CPC

- C07D 403/14: containing three or more hetero rings
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- C07D 409/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

## Claims

### Claim 1

A novel compound represented by the following general formula:
wherein X is selected from the group consisting of C═O, C═S, CR4R5, O, S, NH, and NR4;
Z is selected from the group consisting of hydrogen, C1 to C8 alkyl, phenyl, hydroxymethyl, —CH2—N(—CH2CH2WCH2CH2—), COCH3, CH2CH2OH, and CH2CH2CH2OH;
W is selected from the group consisting of O, S, CH2 and NCH3;
R1 is selected from the group consisting of hydrogen and CH3;
R3 is selected from the group consisting of hydrogen, halogen, C1 to C8 alkyl, phenyl, hydroxymethyl, COCH3, CH2CH2OH, CH2CH2CH2OH and [C(R2)2]cN(R2)2, wherein R2 is selected from the group consisting of hydrogen, halogen, NO2, CN, C1 to C4 alkyl or aryl, and N(R2)2 may form a 3 to 7 membered heterocyclic ring, and said heterocyclic ring may be substituted with one or more of R2; and [C(R2)2]c may form a 3 to 7 membered carbocyclic or heterocyclic ring;
R4 and R5 may be selected from the group consisting of hydrogen, halogen, NO2, CN, C1 to O8 alkyl and aryl; or CR4R5 may form a 3 to 7 membered carbocyclic or heterocyclic ring;
A is 3 to 7 membered heterocyclic ring;
X′ is selected from the group consisting of
and
B may be selected from the group consisting of hydrogen, hydroxy, C1 to C8 alkyl, aryl and CR4R5 wherein CR4R5 may form a 3 to 7 membered carbocyclic or heterocyclic ring;
a is 0 or an integer of from 1 to 5, preferably 1 to 3;
c is 0 or an integer of from 1 to 4,
d is an integer of from 2 to 5;
the wavy line represents a E or Z bond and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein A is a 5 or 6 membered heteroaryl radical represented by formula III below:
wherein said heteroaryl radical is selected from the group consisting of:
R is selected from the group consisting of hydrogen, halogen, C1 to C8 alkyl, CF3, OCF3, OCF2H, CH2CN, CN, SR2, (CR7R8)cC(O)OR2, C(O)N(R2)2, (CR7R8)cOR2, HNC(O)R2, C(O)NR2(CR7R8)cN(R2)2, NR2C(O)(CR7R8)cN(R2)2, HN—C(O)OR2, (CR7R8)cOC(O)(CR7R8)cN(R2)2, (CR7R8)cN(R2)2, SO2(CR7R8)cN(R2)2, OP(O)(OR2)2, OC(O)OR2, OCH2O, HN—CH═CH, —N(COR2)CH2CH2, HC═N—NH, N═CH—S, O(CR7R8)d—R6, (CR7R8)c—R6 and (CR7R8)cNR2(CR7R8)dR6 wherein R6 is selected from the group consisting of halogen, 3-fluoropyrrolidinyl, piperidinyl, 4-fluoropiperidinyl, N-methylpiperazinyl, 2,6-dimethylmorpholinyl, 3-fluoropiperidinyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyrrolinyl, pyrrolidinyl, methyl isonipecotate, N-(2-methoxyethyl)-N-methylamyl, 1,2,3,6-tetrahydropyridinyl, morpholinyl, hexamethyleneiminyl, piperazinyl-2-one, piperazinyl, N-(2-methoxyethyl)ethylaminyl, thiomorpholinyl, heptamethyleneiminyl, 1-piperazinylcarboxaldehyde, 2,3,6,7-tetrahydro-(1H)-1,4-diazepinyl-5(4H)-one, N-methylhomopiperazinyl, (3-dimethylamino)pyrrolidinyl, N-(2-methoxyethyl)-N-propylaminyl, isoindolinyl, nipecotamidinyl, isonipecotamidinyl, 1-acetylpiperazinyl, 3-acetamidopyrrolidinyl, trans-decahydroisoquinolinyl, cis-decahydroisoquinolinyl, N-acetylhomopiperazinyl, 3-(diethylamino)pyrrolidinyl, 1,4-dioxa-8-azaspiro[4.5]decaninyl, 1-(2-methoxyethyl)-piperazinyl, 2-pyrrolidin-3-ylpyridinyl, 4-pyrrolidin-3-ylpyridinyl, 3-(methylsulfonyl)pyrrolidinyl, 3-picolylmethylaminyl, 2-(2-methylaminoethyl)pyridinyl, 1-(2-pyrimidyl)-piperazinyl, 1-(2-pyrazinyl)-piperazinyl, 2-methylaminomethyl-1,3-dioxolane, 2-(N-methyl-2-aminoethyl)-1,3-dioxolane, 3-(N-acetyl-N-methylamino)pyrrolidinyl, 2-methoxyethylaminyl, tetrahydrofurfurylaminyl, 4-aminotetrahydropyran, 2-amino-1-methoxybutane, 2-methoxyisopropylaminyl, 1-(3-aminopropyl)imidazole, histamyl, N,N-diisopropylethylenediaminyl, 1-benzyl-3-aminopyrrolidyl 2-(aminomethyl)-5-methylpyrazinyl, 2,2-dimethyl-1,3-dioxolane-4-methanaminyl, (R)-3-amino-1-N—BOC-pyrrolidinyl, 4-amino-1,2,2,6,6-pentamethylpiperidinyl, 4-aminomethyltetrahydropyran, ethanolamine and alkyl-substituted derivatives thereof; provided said alkyl or phenyl radicals may be substituted with one or two halo, hydroxy or lower alkyl amino radicals or said alkyl radicals may include enchained nitrogen or oxygen atoms, i.e. oxa or imino radicals, as, for example, in polyethylene(oxy)radicals and wherein R7 and R8 may be selected from the group consisting of H, hydroxyl, halogen, and C1 to C4 alkyl and CR7R8 may form a carbocyclic ring of from 3 to 6 carbons.

### Claim 3 (depends on 2)

The compound of claim 2 wherein X is C═O or CR4R5.

### Claim 4 (depends on 3)

The compound of claim 3 wherein R4 and R5 are hydrogen.

### Claim 5 (depends on 4)

The compound of claim 4 wherein B is a 5 or 6 membered aryl radical represented by formula III below:
wherein said aryl radical is selected from the group consisting of:

### Claim 6 (depends on 5)

The compound of claim 5 wherein R is (CR7R8)cNR2(CR7R8)dR6 wherein R6 is selected from the group consisting of pyrrolidinyl, 3-fluoropyrrolidinyl, piperidinyl, 4-fluoropiperidinyl, N-methylpiperazinyl, morpholinyl, 2,6-dimethylmorpholinyl, thiomorpholinyl.

### Claim 7 (depends on 5)

The compound of claim 5 wherein Z, R1 and R3 are H.

### Claim 8 (depends on 5)

The compound of claim 5 wherein X′ is selected from the group consisting of
and wherein B is selected from the group consisting of 5-membered heterocyclic aryl radicals and 6-membered carbocyclic aryl radicals.

### Claim 9 (depends on 8)

The compound of claim 8 wherein X is
and wherein B is selected from the group consisting of 5-membered heterocyclic aryl radicals and 6-membered carbocyclic aryl radicals, and wherein B comprises one oxygen or sulfur atom or two nitrogen atoms.

### Claim at position 10

10-12. (canceled)

### Claim 12 (depends on 9)

The compound of claim 9 wherein B is phenyl.

### Claim 13

(canceled)

### Claim 15 (depends on 4)

The compound of claim 4 wherein a is 1 or 2 and at least one R is H or OH.

### Claim 16 (depends on 9)

The compound of claim 9 wherein a is 1 and R is selected from the group consisting of carboxylic acid radicals, and 5 or 6 membered heterocyclic radicals wherein the heterocyclic ring includes a first enchained nitrogen atom and optionally, an enchained oxygen atom or a second enchained nitrogen atom.

### Claim 17 (depends on 16)

The compound of claim 16 wherein R includes a carboxylic acid radical which is covalently bonded to the phenyl group through a ethylenyl or a propylenyl group.

### Claim 18

(canceled)

### Claim 19 (depends on 16)

The compound of claim 16 wherein R includes a heterocyclic ring which is directly bonded to the phenyl group atom or indirectly through a polymethylene group wherein, in either case, said bond is through an enchained nitrogen atom, and wherein the heterocyclic ring is selected from the group consisting of pyrrolidine, morpholine, piperazine and piperidine.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The compound of claim 19 wherein said heterocyclic ring is substituted with a lower alkyl or a hydroxyl radical.

### Claim 22 (depends on 16)

The compound of claim 16 wherein R is

### Claim 23 (depends on 8)

The compound of claim 8 wherein B is selected from the group consisting of furyl, thienyl, pyrazole, phenyl, and imidazole and lower alkyl functionalized derivatives thereof.

### Claim 24 (depends on 16)

The compound of claim 16 wherein R is

### Claim 25

(canceled)

### Claim 26 (depends on 7)

The compound of claim 7 wherein B is selected from the group consisting of pyrazole, furyl, thienyl, phenyl, and functionalized derivatives thereof.

### Claim at position 25

-30. (canceled)

### Claim 31 (depends on 1)

A method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of carcinoma, sarcoma, leukemia, erythromblastoma, glioblastoma, meningioma, astrocytoma, melanoma, myoblastoma, brain cancer, bladder cancer, ovarian cancer, gastric cancer, pancreas cancer, colon cancer, blood cancer, lung cancer, bone cancer, diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, arthritis and restenosis, hepatic cirrhosis, atherosclerosis and surgical adhesions, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection and glomerulopathies, psoriasis, diabetes mellitus, wound healing, inflammation and neurodegenerative diseases the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

### Claim at position 27

32-33. (canceled)
